At sammenligne steady- state farmakokinetisk profil for anagrelid og dets aktive metabolit hos unge (18- 50 år) vs. ældre (≥ 65 år) patienter med essentiel trombocytæmi (ET).
To compare the steady state pharmacokinetic profile of anagrelide and its active metabolite in young (18-50 years) versus elderly (≥ 65 years) essential thrombocythaemia (ET) patients.